Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ESTELAMARI RODRIGUEZ

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1194887034
CMS profile
144552
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$30,164.63

120 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ESTELAMARI RODRIGUEZ

NPI 1194887034 · CMS profile ID 144552

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194887034?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194887034?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194887034?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ESTELAMARI RODRIGUEZ, NPI 1194887034, CMS profile ID 144552, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 120 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1194887034?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

120 matching records · $30,164.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 120 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 120.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $1,725.0007/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447832 CMS
Daiichi Sankyo Inc. $23.3307/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475401 CMS
Gilead Sciences, Inc. $58.5207/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133797279 CMS
Alexion Pharmaceuticals, Inc. $19.5006/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110540191 CMS
AstraZeneca Pharmaceuticals LP $69.3806/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547786 CMS
ARRAY BIOPHARMA INC $16.2206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131568178 CMS
Daiichi Sankyo Inc. $2.0706/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475393 CMS
Daiichi Sankyo Inc. $23.4906/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475395 CMS
Daiichi Sankyo Inc. $4.9706/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475399 CMS
PFIZER INC. $12.2806/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131612023 CMS
PFIZER INC. $14.5806/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131617104 CMS
AstraZeneca Pharmaceuticals LP $24.9406/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110546459 CMS
Regeneron Healthcare Solutions, Inc. $34.7606/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148313 CMS
Regeneron Healthcare Solutions, Inc. $30.0406/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148315 CMS
PFIZER INC. $150.0006/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131447126 CMS
Immunocore Limited $22.2005/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103097295 CMS
Novocure Inc. $40.0305/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123335279 CMS
Merck Sharp & Dohme LLC $18.2005/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141802203 CMS
ARRAY BIOPHARMA INC $31.4305/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131318320 CMS
E.R. Squibb & Sons, L.L.C. $14.7605/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101823034 CMS
E.R. Squibb & Sons, L.L.C. $15.9905/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101823053 CMS
E.R. Squibb & Sons, L.L.C. $16.7605/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101823085 CMS
E.R. Squibb & Sons, L.L.C. $125.0005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101823089 CMS
Janssen Biotech, Inc. $7.9005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078446191 CMS
Janssen Biotech, Inc. $18.6705/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078446843 CMS
Janssen Biotech, Inc. $1.0505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078448383 CMS
Janssen Biotech, Inc. $29.7005/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078444717 CMS
AstraZeneca Pharmaceuticals LP $1,665.0005/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110533340 CMS
AstraZeneca Pharmaceuticals LP $28.4105/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110532794 CMS
Daiichi Sankyo Inc. $24.0804/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475379 CMS
Amgen Inc. $1,947.0004/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117668839 CMS
AstraZeneca Pharmaceuticals LP $63.4504/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126677788 CMS
Janssen Biotech, Inc. $31.3604/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078446730 CMS
Daiichi Sankyo Inc. $53.4404/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089475363 CMS
AstraZeneca Pharmaceuticals LP $2,220.0004/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110546339 CMS
Merck Sharp & Dohme LLC $17.7904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141802205 CMS
PFIZER INC. $113.5104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131566761 CMS
AstraZeneca Pharmaceuticals LP $27.2404/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110555174 CMS
Janssen Biotech, Inc. $16.4804/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078445543 CMS
Regeneron Healthcare Solutions, Inc. $120.7104/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114148311 CMS
Pharmacosmos Therapeutics Inc. $18.0904/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154825589 CMS
Janssen Biotech, Inc. $2,997.5003/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078450159 CMS
E.R. Squibb & Sons, L.L.C. $17.0103/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101823013 CMS
Lilly USA, LLC $16.6003/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134974438 CMS
Janssen Biotech, Inc. $142.6203/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078443329 CMS
Janssen Biotech, Inc. $31.0803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078447485 CMS
Janssen Biotech, Inc. $130.7903/07/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078450540 CMS
Janssen Biotech, Inc. $294.7003/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078450481 CMS
PFIZER INC. $1,080.0003/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131310948 CMS
ARRAY BIOPHARMA INC $33.2703/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131301118 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $42,585.20 296
PY2020 $805.86 11
PY2021 $16,856.71 16
PY2022 $17,494.91 35
PY2023 $15,065.14 50
PY2024 $30,164.63 120
PY2025 $51,015.99 120

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $435,281.05 47
PY2024 Principal investigator $249,478.57 11
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $151,780.41 4
PY2022 Principal investigator $86,717.05 5
PY2020 Principal investigator $3,658.16 2
PY2019 Principal investigator $51,696.01 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $35,559.63 12/31/2025 Non-covered Recipient Entity
University of Miami Sylvester Comprehensive Cancer Center - Aventura
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928916
Principal investigator 1 Janssen Research & Development, LLC $22,070.00 12/29/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175391171
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $952.00 12/26/2025 Non-covered Recipient Entity
University Of Miami
Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC) No dispute reported 06/30/2026 1235992485
Principal investigator 1 Genentech, Inc. $4,531.00 12/18/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678698
Principal investigator 1 Daiichi Sankyo Inc. $976.00 12/15/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI
DS7300-188 No dispute reported 06/30/2026 1223386630
Principal investigator 1 Daiichi Sankyo Inc. $4,124.00 12/15/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318420
Principal investigator 1 Daiichi Sankyo Inc. $15.50 12/08/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386267
Principal investigator 1 Daiichi Sankyo Inc. $46.50 12/08/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386269
Principal investigator 1 Daiichi Sankyo Inc. $18.25 12/08/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386271
Principal investigator 1 Daiichi Sankyo Inc. $11.55 12/08/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386273
Principal investigator 1 Daiichi Sankyo Inc. $20.85 12/08/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386275
Principal investigator 1 Daiichi Sankyo Inc. $2,560.00 11/19/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318414
Principal investigator 1 Genentech, Inc. $4,531.00 11/18/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678696
Principal investigator 1 Daiichi Sankyo Inc. $4,506.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318408
Principal investigator 1 Daiichi Sankyo Inc. $6,374.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318412
Principal investigator 1 Daiichi Sankyo Inc. $3,124.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318422
Principal investigator 1 Daiichi Sankyo Inc. $4,406.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318424
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318426
Principal investigator 1 Daiichi Sankyo Inc. $3,124.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318428
Principal investigator 1 Daiichi Sankyo Inc. $4,219.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318430
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/03/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318436
Principal investigator 1 Daiichi Sankyo Inc. $3,000.00 10/17/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318410
Principal investigator 1 Daiichi Sankyo Inc. $3,500.00 10/17/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318416
Principal investigator 1 Daiichi Sankyo Inc. $205.00 10/17/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318418
Principal investigator 1 Daiichi Sankyo Inc. $1,515.00 10/17/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318432
Principal investigator 1 Daiichi Sankyo Inc. $5,440.00 10/17/2025 Non-covered Recipient Entity
University Of Miami
DS7300-188 No dispute reported 06/30/2026 1225318434
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,519.36 10/17/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MIAMI HOSPITAL
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272461
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386257
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386259
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386261
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386263
Principal investigator 1 Daiichi Sankyo Inc. $15.50 10/13/2025 Non-covered Recipient Entity
University Miami Miller School Of Medicine
DS7300-188 No dispute reported 06/30/2026 1223386265
Principal investigator 1 Genentech, Inc. $9,900.00 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678692
Principal investigator 1 Genentech, Inc. $40,220.00 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678694
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $27,025.00 09/30/2025 Non-covered Recipient Entity
University Of Miami
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235992483
Principal investigator 1 Genentech, Inc. $25,039.00 08/22/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678686
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $93,521.76 08/22/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MIAMI HOSPITAL
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272447
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,284.07 07/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MIAMI HOSPITAL
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272423
Principal investigator 1 Genentech, Inc. $26,628.00 06/10/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI OFFICE OF RESEARCH ADMINISTRATION
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARAS No dispute reported 06/30/2026 1211678676
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,953.20 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280396
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $680.00 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $988.48 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280400
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 05/28/2025 Non-covered Recipient Entity
UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280402
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,096.06 04/23/2025 Covered Recipient Teaching Hospital
University Of Miami Hospital
A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% No dispute reported 06/30/2026 1235999760
Principal investigator 1 Merck Sharp & Dohme LLC $16,418.00 02/24/2025 Non-covered Recipient Entity
University of Miami Hospital and Clinics, Sylvester Cancer Center
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab MK-3475 in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater than No dispute reported 06/30/2026 1232928914
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $28,420.70 02/05/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MIAMI HOSPITAL
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,240.64 01/03/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF MIAMI HOSPITAL
AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION, PHASE 1A/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-500, A NOVEL STIMULATOR OF INTERFERON GENES AGONIST, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223272257